Rabbit Monoclonal Antibodies Developed for Immunohistochemistry Applications
|
By LabMedica International staff writers Posted on 02 Mar 2010 |
|
A new range of rabbit monoclonal and polyclonal antibodies has been developed for immunohistochemistry (IHC) applications. A rabbit custom antibody service is also available.
Antibodies produced by rabbits are reported often to provide superior antigen recognition, greater specificity, and better consistency than those offered by mice. Rabbit antibodies can recognize specific antigens and epitopes that are not immunogenic in mice or rats. These antibodies can sometimes also offer higher working titers and may therefore help to lower laboratory costs. By using rabbit monoclonal antibodies (RMAbs), researchers can benefit from these unique qualities especially in the area of immunohistochemistry. Use of RMAbs technology provides critical information to researchers regarding the distribution and localization of biomarkers, and differentially expressed proteins in different parts of a biologic tissue.
AMSBIO (Abingdon, UK) offers a range of over 3,500 antibodies for immunohistochemistry including rabbit monoclonal, polyclonal, and mouse monoclonal antibodies (MAbs). Included in this range are antibodies that have been characterized to work on FFPE sections, renowned for their robust, highly sensitive, and specific characteristics. Many of these antibodies have been CE marked. The AMSBIO SP1 Estrogen Receptor antibody is now recommended as the gold standard by leading breast cancer experts and distributed worldwide.
AMS Biotechnology (AMSBIO) is a leading international provider of products and custom services for life sciences research. The AMSBIO range includes over 23,000 polyclonal and monoclonal antibodies, peptides, recombinant proteins, extracellular matrix, molecular detection reagents, tissue DNA, RNA, protein, and microarray products. Key research areas include apoptosis, cell invasion and migration, cell signaling, DNA damage, electrophoresis, glycobiology, posttranslational modification, and stem cell biology.
Related Links:
AMSBIO
Antibodies produced by rabbits are reported often to provide superior antigen recognition, greater specificity, and better consistency than those offered by mice. Rabbit antibodies can recognize specific antigens and epitopes that are not immunogenic in mice or rats. These antibodies can sometimes also offer higher working titers and may therefore help to lower laboratory costs. By using rabbit monoclonal antibodies (RMAbs), researchers can benefit from these unique qualities especially in the area of immunohistochemistry. Use of RMAbs technology provides critical information to researchers regarding the distribution and localization of biomarkers, and differentially expressed proteins in different parts of a biologic tissue.
AMSBIO (Abingdon, UK) offers a range of over 3,500 antibodies for immunohistochemistry including rabbit monoclonal, polyclonal, and mouse monoclonal antibodies (MAbs). Included in this range are antibodies that have been characterized to work on FFPE sections, renowned for their robust, highly sensitive, and specific characteristics. Many of these antibodies have been CE marked. The AMSBIO SP1 Estrogen Receptor antibody is now recommended as the gold standard by leading breast cancer experts and distributed worldwide.
AMS Biotechnology (AMSBIO) is a leading international provider of products and custom services for life sciences research. The AMSBIO range includes over 23,000 polyclonal and monoclonal antibodies, peptides, recombinant proteins, extracellular matrix, molecular detection reagents, tissue DNA, RNA, protein, and microarray products. Key research areas include apoptosis, cell invasion and migration, cell signaling, DNA damage, electrophoresis, glycobiology, posttranslational modification, and stem cell biology.
Related Links:
AMSBIO
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Benchtop Thermomixer
Biometra TS1 ThermoShaker
HPV Test
Allplex HPV28 Detection
Latest Immunology News
- Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
- Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
- Study Points to Autoimmune Pathway Behind Long COVID Symptoms
- Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
- Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
- Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
- Biomarkers and Molecular Testing Advance Precision Allergy Care
- Point-of-Care Tests Could Expand Access to Mpox Diagnosis
- T-Cell Senescence Profiling May Predict CAR T Responses
- Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
- Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
- Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Channels
Clinical Chemistry
view channel
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more
Plasma Vitamin C Levels Associated with Brain Structure and Connectivity in Aging
Previous studies have linked vitamin C–rich diets with lower risk of cognitive impairment in older adults. However, few investigations have directly examined blood plasma vitamin C in relation to brain... Read more
Mass Spectrometry Detects Tumor Metabolites for Cancer Monitoring
Cancer’s altered metabolism complicates how clinicians detect and monitor tumors, because nutrient use can shift with context and time. Measuring small-molecule metabolites that distinguish malignant from... Read more
Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read moreMolecular Diagnostics
view channel
Ultrasensitive HPV Blood Test Predicts Early Recurrence in Head and Neck Cancer
Human papillomavirus (HPV)-associated head and neck cancers are frequently treated with surgery, but some patients experience recurrence due to residual microscopic disease. Postoperative decisions about... Read more
New Library Normalization and Amplification Tools Support Oncology Sequencing
High-throughput next-generation sequencing (NGS) laboratories continue to grapple with uneven library pooling and amplification artifacts that can degrade variant calling accuracy and increase reruns.... Read more
Hematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read more
Microbiology
view channel
TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
Congenital TORCH infections can be asymptomatic during pregnancy yet cause stillbirth, birth defects, and lifelong disability in infants. Many regions still lack robust surveillance to guide testing and... Read more
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Pathology
view channel
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
Accurate classification of brain and spinal cord tumors increasingly depends on molecular profiling alongside histology, but access to such testing remains limited and results can take about two weeks.... Read more
IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
Deficient DNA mismatch repair is an established predictive biomarker for response to immune checkpoint inhibitors, yet access to standardized assessment has varied across tumor types. Cancer remains the... Read more
Technology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read more
Industry
view channel
Open-Source Consortium Aims to Standardize Digital Pathology Workflows
Digital pathology is expanding rapidly as laboratories adopt whole-slide imaging and computational tools to meet growing diagnostic and biomarker-testing demand. However, fragmented software infrastructure... Read more
